European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
Concurrent chemoradiotherapy with docetaxel, cisplatin, and fluorouracil for patients with advanced external auditory canal squamous cell carcinoma: comparison with cisplatin-based concurrent chemoradiotherapy.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ueki Yushi, Ohno Yuki, Ohshima Shusuke, Yokoyama Yusuke, Omata Jo, Takahashi Takeshi, Shodo Ryusuke, Saijo Kohei, Ohtaki Kohei, Matsuyama Hiroshi, Aoyama Riku, Ogi Manabu, Takahashi Nao, Horii Arata
Аннотация
PURPOSE: Concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin (CDDP), and fluorouracil (5-FU) (i.e. TPF regimen) has yielded favourable outcomes in treating advanced external auditory canal squamous cell carcinoma (EACSCC). However, safety and efficacy have not been compared across TPF-CCRT and CDDP-based regimens. This study thus aimed to assess the feasibility, safety, and efficacy of TPF-CCRT versus CDDP-CCRT.
METHODS: This retrospective study evaluated 20 patients with T3/T4 EACSCC who underwent CCRT between 2007 and 2023. During radiotherapy, the TPF group (n = 10) received two cycles of 50 mg/m2 docetaxel and 60 mg/m2 CDDP on day 1, plus 600 mg/m2 5-FU on days 1-4. Meanwhile, the CDDP group (n = 10) received three cycles of CDDP (80 mg/m2) triweekly or two cycles of CDDP (60 mg/m2) on day 1 and 5-FU (600 mg/m2/day) on days 1-4 during RT. Treatment compliance, incidence of adverse events, progression-free survival (PFS), and overall survival (OS) were compared between the groups.
RESULTS: All patients completed radiotherapy. The incidence of grade ≥ 3 adverse events was not significantly different between the TPF and CDDP groups, but leukopenia (any grade) and alopecia occurred more frequently in the TPF group. Two-year PFS (80% vs. 20%, p < 0.01) and OS rates (100% vs. 40%, p < 0.01) were significantly higher in the TPF group.
CONCLUSION: Compared with CDDP-CCRT, TPF-CCRT has excellent feasibility and efficacy and acceptable toxicity for advanced EACSCC, making it a promising treatment option for this malignancy.
METHODS: This retrospective study evaluated 20 patients with T3/T4 EACSCC who underwent CCRT between 2007 and 2023. During radiotherapy, the TPF group (n = 10) received two cycles of 50 mg/m2 docetaxel and 60 mg/m2 CDDP on day 1, plus 600 mg/m2 5-FU on days 1-4. Meanwhile, the CDDP group (n = 10) received three cycles of CDDP (80 mg/m2) triweekly or two cycles of CDDP (60 mg/m2) on day 1 and 5-FU (600 mg/m2/day) on days 1-4 during RT. Treatment compliance, incidence of adverse events, progression-free survival (PFS), and overall survival (OS) were compared between the groups.
RESULTS: All patients completed radiotherapy. The incidence of grade ≥ 3 adverse events was not significantly different between the TPF and CDDP groups, but leukopenia (any grade) and alopecia occurred more frequently in the TPF group. Two-year PFS (80% vs. 20%, p < 0.01) and OS rates (100% vs. 40%, p < 0.01) were significantly higher in the TPF group.
CONCLUSION: Compared with CDDP-CCRT, TPF-CCRT has excellent feasibility and efficacy and acceptable toxicity for advanced EACSCC, making it a promising treatment option for this malignancy.